In this study, we showed that TRPM7 is strikingly upregulated in reactive astrocytes in both active and chronic active MS lesions and that TGF‐β1 treatment is able to enhance astrocytic TRPM7 expression in vitro. Here, TGFB1 is linked to myeloid sarcoma.